Evidence map›Paper›PMID 27394166›Full record

ReviewPharmacological research2016

Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

Karima Ait-Aissa, Johnathan D Ebben, Andrew O Kadlec, Andreas M Beyer

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacological research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Telomerase therapy attenuates cardiotoxic effects of doxorubicin.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  7. Review
  8. Review
  9. Review
  10. Independent and Combined Effects of Telomere Shortening and mtDNAInternational journal of molecular sciences · 2019
    Article
  11. Telomeres as Therapeutic Targets in Heart Disease.JACC. Basic to translational science · 2019
    Review
  12. Telomerase: Location, Location, Location?Arteriosclerosis, thrombosis, and vascular biology · 2018
    Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Karima Ait-AissaDepartment of Medicine, Medical College of Wisconsin, United States; Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, United States.
Johnathan D EbbenDepartment of Pharmacology & Toxicology, Medical College of Wisconsin,, United States; Cancer Center, Medical College of Wisconsin, United States.
Andrew O KadlecDepartment of Medicine, Medical College of Wisconsin, United States; Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, United States.
Andreas M BeyerDepartment of Medicine, Medical College of Wisconsin, United States; Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, United States. Electronic address: abeyer@mcw.edu.
Medical College of Wisconsin · US

Funding

Medical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7M
Mechanism of Flow-Induced Dilation in the Human MicrocirculationR01HL113612 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI GUTTERMAN, DAVID D. · 2013 to 2016
$1.7M
Differentiation of mitochondrial vs. nuclear function of telomeraseR21OD018306 · OD · MEDICAL COLLEGE OF WISCONSIN · PI BEYER, ANDREAS M · 2014 to 2015
$411k
NHLBI NIH HHS R01 HL113612NIGMS NIH HHS T32 GM080202NIH HHS R21 OD018306
6 · The paper itself

Abstract

Aging, cancer, and chronic disease have remained at the forefront of basic biological research for decades. Within this context, significant attention has been paid to the role of telomerase, the enzyme responsible for lengthening telomeres, the nucleotide sequences located at the end of chromosomes found in the nucleus. Alterations in telomere length and telomerase activity are a common denominator to the underlying pathology of these diseases. While nuclear-specific, telomere-lengthening effects of telomerase impact cellular/organismal aging and cancer development, non-canonical, extra-nuclear, and non-telomere-lengthening contributions of telomerase have only recently been described and their exact physiological implications are ill defined. Although the mechanism remains unclear, recent reports reveal that the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), regulates levels of mitochondrial-derived reactive oxygen species (mtROS), independent of its established role in the nucleus. Telomerase inhibition has been the target of chemotherapy (directed or indirectly) for over a decade now, yet no telomerase inhibitor is FDA approved and few are currently in late-stage clinical trials, possibly due to underappreciation of the distinct extra-nuclear functions of telomerase. Moreover, evaluation of telomerase-specific therapies is largely limited to the context of chemotherapy, despite reports of the beneficial effects of telomerase activation in the cardiovascular system in relation to such processes as endothelial dysfunction and myocardial infarction. Thus, there is a need for better understanding of telomerase-focused cell and organism physiology, as well as development of telomerase-specific therapies in relation to cancer and extension of these therapies to cardiovascular pathologies. This review will detail findings related to telomerase and evaluate its potential to serve as a therapeutic target.

Indexed as

AnimalsAntineoplastic AgentsCardiovascular AgentsCardiovascular DiseasesEnzyme ActivationEnzyme ActivatorsEnzyme InhibitorsHumansMolecular Targeted TherapyNeoplasmsSignal TransductionTelomeraseTelomere HomeostasisTelomere ShorteningAntineoplastic AgentsCardiovascular AgentsEnzyme ActivatorsEnzyme InhibitorsTelomeraseAgingCancerCardiovascular diseaseReactive oxygen speciesTelomerase

Identifiers

PMID27394166
PMCPMC5026584
OpenAlexW2463090465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.